← All trials
NCT05372016
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 19, 2020
- Primary completion
- Jul 16, 2021
- Completion date
- Nov 5, 2021
- First posted
- May 12, 2022
- Last posted
- May 12, 2022
- Enrollment
- 1200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Shanghai Bovax Biotechnology Co., Ltd.Lead sponsor
- Shanghai Bovax Biotechnology Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.